Mpox Virus Clade Ib Congo: Introduction & Spread
- What: The FDA approved Arexvy, a respiratory syncytial virus (RSV) vaccine, for adults aged 60 years and older.
- When: Approved may 3, 2023, with data published September 18, 2025, in the New England Journal of Medicine.
- Why it Matters: RSV causes meaningful illness and hospitalization in older adults, and this is the first widely available vaccine to prevent it.
“`html
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms.However, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Before the availability of a vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the united States. The virus weakens the respiratory system, making individuals more vulnerable to secondary infections and exacerbating existing conditions like COPD and heart failure.
The impact of RSV extends beyond individual health. hospitalizations strain healthcare resources, particularly during peak RSV season – typically fall and winter. The economic burden associated with RSV-related illness is considerable, encompassing medical costs, lost productivity, and caregiver time.
The Arexvy Vaccine: How it effectively works and Trial Results
Arexvy, developed by GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is found on the surface of the RSV virus and is crucial for the virus to enter cells.By presenting this protein to the immune system, the vaccine triggers the production of antibodies that can neutralize the virus and prevent infection.
The pivotal Phase 3 trial,published in the New England Journal of Medicine on September 18,2025,involved over 12,600 adults aged 60 years and older. The results demonstrated a vaccine efficacy of 82.6% against RSV-associated lower respiratory tract disease (LRTD) – defined as illness requiring medical intervention – in participants without underlying conditions. Efficacy was 66.3% in those with underlying conditions.
Importantly, the trial also assessed the safety profile of Arexvy. While some participants experienced mild to moderate side effects, such as pain at the injection site, fatigue, and muscle aches, serious adverse events were rare and not definitively linked to the vaccine. A small number of participants experienced Guillain-Barré syndrome, a rare neurological disorder, but the causal relationship remains under investigation.
| Outcome | vaccine Group (Efficacy %) | placebo Group (Rate per 1000 Person-Years) |
|---|---|---|
| RSV-associated LRTD (No Underlying Conditions) | 82.6 | 14.2 |
| RSV-associated LRTD (With Underlying Conditions) | 66.3 | 21.4 |
| RSV-associated Hospitalization | 65.2 | 8.7 |
Who Should Get the RSV Vaccine?
The Centers for Disease Control and Prevention (CDC) recommends that adults aged 60 years and older may receive a dose of RSV vaccine, based on shared clinical decision-making with their healthcare provider. This means a discussion about individual risk factors, potential benefits, and preferences is crucial.
Individuals at higher risk of severe RSV illness